Trimetazidine may protect the myocardium during cardiac surgery

Heart Surgery Forum

Volumn 12, Issue 3, 2009, Pages

  Iskesen, Ihsan ^a   Kurdal, Adnan Taner ^a   Eserdag, Mazhar ^a   Cerrahoglu, Mustafa ^a   Sirin, Bekir Hayrettin ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; LACTIC ACID; MYOGLOBIN; TRIMETAZIDINE; TROPONIN T; CARDIOTONIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEART MUSCLE; HEART MUSCLE INJURY; HEART PROTECTION; HEMODYNAMICS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TISSUE LEVEL; HEART MUSCLE ISCHEMIA; MIDDLE AGED; TREATMENT OUTCOME;

CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 70349235761     PISSN: 10983511     EISSN: 15226662     Source Type: Journal    
DOI: 10.1532/HSF98.20081133     Document Type: Article

References (13)

1. Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. 2008. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol 6:282-91.
2. Barsotti A, Di Napoli P. 2004. Trimetazidine and cardioprotection during ischemia-reperfusion. Ital Heart J 5:29-36.
3. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. 2008. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil 15:533-40.
4. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. 2006. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J 70:1169-73.
5. Kara AF, Demiryürek S, Celik A, Tarakcioǧlu M, Demiryülu M, Demiryürek AT. 2004. Effects of trimetazidine on myocardial preconditioning in anesthetized rats. Eur J Pharmacol 503:135-45.
6. Kara AF, Demiryürek S, Celik A, Tarakcioǧlu M, Demiryürek AT. 2006. Effects of chronic trimetazidine treatment on myocardial preconditioning in anesthetized rats. Fundam Clin Pharmacol 20:449-59.
7. Labrou A, Giannoglou G, Zioutas D, Fragaris N, Katsaris G, Louridas G. 2007. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 7:143-50.
8. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. 2003. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:33-7.
9. Penttila K, Koukkunen H, Halinen M, et al. 2002. Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain. Clin Biochem 35:647-53.
10. Sellier P, Broustet JP. 2003. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 3:361-9.
11. Silveira Filho LM, Petrtucci O Jr, Carmo MR, et al. 2008. Trimetazidine as cardioplegia addictive without pre-treatment does not improve myocardial protection: study in a swine working heart model. Rev Bras Cir Cardiovasc 23:224-34.
12. Singh D, Chopra K. 2004. Effect of trimetazidine on renal ischemia/reperfusion injury in rats. Pharmacol Res 50:623-9.
13. Stanley WC, Marzilli M. 2003. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 17:133-45.